Nabi obtains rights to ProMetic's hyperimmune immunoglobulin extraction technology

By Lisa Kerner

Charlotte, N.C., Aug. 29 - Nabi Biopharmaceuticals obtained exclusive rights to use a novel hyperimmune immunoglobulin extraction technology from ProMetic Life Sciences, Inc. in the manufacture of its pipeline hyperimmune products.

Nabi has already assessed ProMetic's fractionation technology on a pilot scale, according to a news release.

With the technology, Nabi expects higher yields of its Civacir [Hepatitis C Immune Globulin (Human)] and Altastaph [Staphylococcus aureus Immune Globulin Intravenous (Human)].

The company also has the option to use ProMetic's technology with its marketed Nabi-HB [Hepatitis B Immune Globulin (Human)] and Nabi-HB Intravenous [Hepatitis B Immune Globulin (Human) Intravenous], as well as other product candidates.

"The advantage of the ProMetic technology is that it affords Nabi Biopharmaceuticals the ability to maximize the yield of specific immunoglobulins from a liter of hyperimmune plasma, and as a result, reduces the cost of manufacturing and increases the capacity for production of some its most promising product candidates," senior vice president research, technical and production operations, Raafat Fahim said in the release.

Nabi is a biopharmaceutical company based in Boca Raton, Fla.

ProMetic is a global biopharmaceutical company based in Montreal.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.